⚕ GalenOps field
←

SITE002-0328

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-03-21

AEs
8
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-25 (study day 17); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-10 (study day 32); relationship: not assessed

moderate assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-05-29 (study day 51); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-05 (study day 58); relationship: N

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-06-05 (study day 58); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-06-22 (study day 75); relationship: not assessed

severe assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-21 (study day 104); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-25 (study day 108); relationship: not assessed

Data queries

No data queries.